Volumetric changes and clinical trajectories in Parkinson’s disease: a prospective multicentric study
J Neurol. 2023-08-31; :
DOI: 10.1007/s00415-023-11947-0
Read on PubMed
Marques A(1)(2)(3), Macias E(4)(5), Pereira B(6), Durand E(4)(5), Chassain C(4)(5), Vidal T(4)(5), Defebvre L(7), Carriere N(7), Fraix V(8), Moro E(8), Thobois S(9)(10)(11), Metereau E(9)(10)(11), Mangone G(12), Vidailhet M(12), Corvol JC(12), Lehéricy S(13), Menjot de Champfleur N(14)(15), Geny C(16), Spampinato U(17)(18), Meissner WG(17)(19)(20)(21), Frismand S(22), Schmitt E(23), Doé de Maindreville A(24), Portefaix C(25)(26), Remy P(27), Fénelon G(27), Houeto JL(28)(29), Colin O(30), Rascol O(31), Peran P(32), Bonny
JM(33)(34), Fantini ML(4)(5), Durif F(4)(5); R2* Study Group.
Author information:
(1)University Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute
Pascal, Clermont-Ferrand, France. .
(2)Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand University
Hospital, Clermont-Ferrand, France. .
(3)Neurology Department, Parkinson Expert Center, CHRU Gabriel Montpied, 63000,
Clermont-Ferrand, France. .
(4)University Clermont Auvergne, CNRS, Clermont Auvergne INP, IGCNC, Institute
Pascal, Clermont-Ferrand, France.
(5)Neurology Department and NS-PARK/FCRIN Network, Clermont-Ferrand University
Hospital, Clermont-Ferrand, France.
(6)Clermont-Ferrand University Hospital, Biostatistics Unit (DRCI),
Clermont-Ferrand, France.
(7)Department of Movement Disorder and NS-PARK/FCRIN Network, Inserm 1172,
University of Lille, Lille, France.
(8)Université Grenoble Alpes, CHU de Grenoble, Service de Neurologie, Grenoble
Institute of Neuroscience, and NS-PARK/FCRIN Network, Grenoble, France.
(9)CNRS, Institut des Sciences Cognitives Marc Jeannerod, UMR 5229 CNRS, Lyon,
France.
(10)Université Claude Bernard, Lyon I, Lyon, France.
(11)Hospices Civils de Lyon, Hôpital Neurologique Pierre Wertheimer, Service de
Neurologie C and NS-PARK/FCRIN Network, Lyon, France.
(12)Département de Neurologie and NS-PARK/FCRIN Network, Sorbonne Université;
Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris; Inserm 1127,
CNRS 7225, CIC Neurosciences, Hôpital Pitié-Salpêtrière, Paris, France.
(13)Département de Neuroradiologie and NS-PARK/FCRIN Network, Sorbonne
Université; Institut du Cerveau-ICM, Assistance Publique Hôpitaux de Paris;
Inserm 1127, CNRS 7225; Hôpital Pitié-Salpêtrière, Paris, France.
(14)Department of Neuroradiology, Montpellier University Hospital Center, Gui de
Chauliac Hospital, Montpellier, France.
(15)I2FH, Institut d’Imagerie Fonctionnelle Humaine, Hôpital Gui de Chauliac,
CHRU de Montpellier, Montpellier, France.
(16)Department of Geriatrics and NS-PARK/FCRIN Network, Montpellier University
Hospital, Montpellier University, Montpellier, France.
(17)Service de Neurologie-Maladies Neurodégénératives and NS-PARK/FCRIN Network,
CHU Bordeaux, 33000, Bordeaux, France.
(18)INCIA-UMR 5287, Team P3TN, CNRS/Université de Bordeaux, Bordeaux, France.
(19)Univ. Bordeaux, CNRS, IMN, UMR 5293, Bordeaux, 33000, Bordeaux, France.
(20)Dept. Medicine, University of Otago, Christchurch, New Zealand.
(21)New Zealand Brain Research Institute, Christchurch, New Zealand.
(22)Department of Neurology and NS-PARK/FCRIN Network, Nancy University Hospital
Center, Nancy, France.
(23)Department of Neuroradiology, Nancy University Hospital Center, Nancy,
France.
(24)Department of Neurology and NS-PARK/FCRIN Network, Hôpital Maison Blanche,
Reims, France.
(25)Department of Radiology, Hôpital Maison Blanche, Reims, France.
(26)CReSTIC Laboratory, University of Reims Champagne-Ardenne, Reims, France.
(27)Centre Expert Parkinson and NS-PARK/FCRIN Network, CHU Henri Mondor; AP-HP
et Equipe Neuropsychologie Interventionnelle, INSERM-IMRB, Faculté de Santé,
Université Paris-Est Créteil et Ecole Normale Supérieure Paris Sorbonne
Université, Créteil, France.
(28)INSERM, CHU de Poitiers, Université de Poitiers, Centre d’Investigation
Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, Poitiers,
France.
(29)CHU-Centre Expert Parkinson de Limoges, Limoges, France.
(30)INSERM, CHU de Poitiers, Université de Poitiers, Centre d’Investigation
Clinique CIC1402; Service de Neurologie and NS-PARK/FCRIN Network, CH Brive la
Gaillarde, Poitiers, France.
(31)Centre Expert Parkinson, Départements de Pharmacologie Clinique et
Neurosciences, Centre d’Investigation Clinique CIC 1436, UMR 1214 TONIC,
NeuroToul and NS-PARK/FCRIN Network, INSERM, CHU de Toulouse et Université de
Toulouse3, Toulouse, France.
(32)ToNIC, Toulouse NeuroImaging Center, Université de Toulouse, INSERM, UPS,
Toulouse, France.
(33)INRAE, UR QuaPA, 63122, Saint-Genès-Champanelle, France.
(34)Nuclear Magnetic Resonance Facility for Agronomy, Food and Health,
AgroResonance, INRAE, 2018, Saint-Genès-Champanelle, France.
BACKGROUND: Longitudinal measures of structural brain changes using MRI in
relation to clinical features and progression patterns in PD have been assessed
in previous studies, but few were conducted in well-defined and large cohorts,
including prospective clinical assessments of both motor and non-motor symptoms.
OBJECTIVE: We aimed to identify brain volumetric changes characterizing PD
patients, and determine whether regional brain volumetric characteristics at
baseline can predict motor, psycho-behavioral and cognitive evolution at one
year in a prospective cohort of PD patients.
METHODS: In this multicentric 1 year longitudinal study, PD patients and healthy
controls from the MPI-R2* cohort were assessed for demographical, clinical and
brain volumetric characteristics. Distinct subgroups of PD patients according to
motor, cognitive and psycho-behavioral evolution were identified at the end of
follow-up.
RESULTS: One hundred and fifty PD patients and 73 control subjects were included
in our analysis. Over one year, there was no significant difference in volume
variations between PD and control subjects, regardless of the brain region
considered. However, we observed a reduction in posterior cingulate cortex
volume at baseline in PD patients with motor deterioration at one year
(p = 0.017). We also observed a bilateral reduction of the volume of the
amygdala (p = 0.015 and p = 0.041) and hippocampus (p = 0.015 and p = 0.053) at
baseline in patients with psycho-behavioral deterioration, regardless of age,
dopaminergic treatment and center.
CONCLUSION: Brain volumetric characteristics at baseline may predict clinical
trajectories at 1 year in PD as posterior cingulate cortex atrophy was
associated with motor decline, while amygdala and hippocampus atrophy were
associated with psycho-behavioral decline.
© 2023. The Author(s), under exclusive licence to Springer-Verlag GmbH Germany.